- Home
- AIHS vs MYNZ Comparison
AIHS vs MYNZ Comparison
Compare AIHS & MYNZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AIHS
- MYNZ
- Stock Information
- Founded
- AIHS 2014
- MYNZ 2021
- Country
- AIHS China
- MYNZ Germany
- Employees
- AIHS N/A
- MYNZ N/A
- Industry
- AIHS Finance: Consumer Services
- MYNZ Biotechnology: Pharmaceutical Preparations
- Sector
- AIHS Finance
- MYNZ Health Care
- Exchange
- AIHS Nasdaq
- MYNZ Nasdaq
- Market Cap
- AIHS 9.5M
- MYNZ 10.5M
- IPO Year
- AIHS 2018
- MYNZ 2021
- Fundamental
- Price
- AIHS $0.90
- MYNZ $3.44
- Analyst Decision
- AIHS
- MYNZ Buy
- Analyst Count
- AIHS 0
- MYNZ 3
- Target Price
- AIHS N/A
- MYNZ $14.00
- AVG Volume (30 Days)
- AIHS 10.4K
- MYNZ 177.3K
- Earning Date
- AIHS 02-14-2025
- MYNZ 04-15-2025
- Dividend Yield
- AIHS N/A
- MYNZ N/A
- EPS Growth
- AIHS N/A
- MYNZ N/A
- EPS
- AIHS N/A
- MYNZ N/A
- Revenue
- AIHS $5,878,700.00
- MYNZ $893,991.00
- Revenue This Year
- AIHS N/A
- MYNZ $20.94
- Revenue Next Year
- AIHS N/A
- MYNZ $18.01
- P/E Ratio
- AIHS N/A
- MYNZ N/A
- Revenue Growth
- AIHS 12.21
- MYNZ N/A
- 52 Week Low
- AIHS $0.74
- MYNZ $0.18
- 52 Week High
- AIHS $1.45
- MYNZ $8.20
- Technical
- Relative Strength Index (RSI)
- AIHS 50.79
- MYNZ 37.70
- Support Level
- AIHS $0.86
- MYNZ $2.72
- Resistance Level
- AIHS $1.04
- MYNZ $5.34
- Average True Range (ATR)
- AIHS 0.06
- MYNZ 0.55
- MACD
- AIHS 0.00
- MYNZ -0.12
- Stochastic Oscillator
- AIHS 23.33
- MYNZ 27.48
About AIHS Senmiao Technology Limited
Senmiao Technology Ltd is a holding company. The company's operating segment includes Automobile Transaction and Related Services focusing on the online ride-hailing industry in the People's Republic of China and Online ride-hailing platform Services through its own platform, Xixingtianxia. It generates maximum revenue from the Automobile Transaction and Related Services segment. Geographically, it derives revenue from China.
About MYNZ Mainz Biomed N.V.
Mainz Biomed NV develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The company's flagship product is ColoAlert, is an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples.